GSKCONS.NS - GlaxoSmithKline Consumer Healthcare Limited

NSE - NSE Real Time Price. Currency in INR
6,247.85
-31.85 (-0.51%)
At close: 3:29PM IST
Stock chart is not supported by your current browser
Previous Close6,279.70
Open6,266.65
Bid0.00 x 0
Ask0.00 x 0
Day's Range6,189.95 - 6,290.00
52 Week Range4,851.00 - 6,325.00
Volume8,574
Avg. Volume10,592
Market Cap262.669B
BetaN/A
PE Ratio (TTM)41.25
EPS (TTM)151.46
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6,272.23
  • Glaxo's Nucala Label Expansion Application Gets FDA Approval
    Zacks3 hours ago

    Glaxo's Nucala Label Expansion Application Gets FDA Approval

    GlaxoSmithKline's (GSK) application to include treatment of eosinophilic granulomatosis with polyangiitis in Nucala's label was approved by the FDA.

  • Glaxo's New Pharma Head Looks to Move Fast, Especially in Cancer
    Bloomberg2 days ago

    Glaxo's New Pharma Head Looks to Move Fast, Especially in Cancer

    GlaxoSmithKline Plc, the U.K.’s biggest drugmaker, signaled it will look to speed development of an experimental cancer treatment as part of its ambition to expand in oncology just two years after selling ...

  • American City Business Journals5 days ago

    GlaxoSmithKline's Rockville chief lays out priorities for 2018

    British pharmaceutical giant GlaxoSmithKline PLC said it finally has a full team in place at its vaccine hub in Rockville and is ready to take on some of the region's most well-known biotech competitors with part of its product lineup. This next year, officials said, will be about taking a leadership position in new vaccine technologies and advancing its priority projects, including a vaccine for shingles as well its vaccine candidate for respiratory syncytial virus, a common respiratory virus that often attacks infants and the elderly — and a key disease target already for major players such as MedImmune and Novavax Inc. "It's really getting down to business and doing the work," said Rip Ballou, vice president and head of GSK's (GSK) Global Vaccines U.S. Research and Development Center in Rockville.

  • Barrons.com7 days ago

    Glaxo Who? Why Gilead's HIV Drug Could Be the 'Greatest of All Time'

    Shares of Gilead Sciences (GILD) are rising Wednesday, helped by a bullish note from Credit Suisse, which argues that its HIV treatment Bictegravir could be a launch that will become "the greatest ...

  • Market Realist7 days ago

    GlaxoSmithKline’s Vaccines Business in 3Q17

    GlaxoSmithKline’s (GSK) Vaccines business reported revenues of ~1.7 billion pounds during 3Q17, reflecting 5.0% growth in revenues compared to 3Q16.

  • GSK, other drugmakers bet on post-Brexit UK science
    Reuters7 days ago

    GSK, other drugmakers bet on post-Brexit UK science

    Britain won a vote of confidence from its economically important life sciences sector on Wednesday as several major drug companies committed to invest in the country under the government's industrial strategy plans after Brexit. The move is welcome news for Prime Minister Theresa May, who has struggled to win over large sections of industry as Britain prepares to leave the European Union. Thanks to the strength of UK universities and the presence of two major pharmaceuticals companies in GlaxoSmithKline and AstraZeneca, the drugs industry has been a bright spot in the British economy for many years.

  • Reuters8 days ago

    PRESS DIGEST- Financial Times - Dec 6

    The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines * Deutsche Bank sends Trump financial details to Mueller ...

  • Drug Companies From Glaxo to J&J Pledge to Make U.K. Investments
    Bloomberg8 days ago

    Drug Companies From Glaxo to J&J Pledge to Make U.K. Investments

    GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. and AstraZeneca Plc are among more than two dozen global pharmaceutical companies pledging to invest funds in the U.K. as part of a multi-billion-pound ...

  • Australian watchdog takes GlaxoSmithKline, Novartis units to court
    Reuters8 days ago

    Australian watchdog takes GlaxoSmithKline, Novartis units to court

    The ACCC alleged that the companies tried to market their two pain relief products, Osteo Gel and Emulgel, as having different levels of impact in treating osteoarthritis, when in fact they are "identically formulated". "We allege that consumers are likely to have been misled into purchasing Osteo Gel thinking that it is different to Emulgel and more effective for treating osteoarthritis conditions, when this is not the case”, ACCC Chairman Rod Sims said.

  • GlaxoSmithKline and the Dividend Mirage
    GuruFocus.com8 days ago

    GlaxoSmithKline and the Dividend Mirage

    The closer you get, the more ephemeral the company's 6% dividend yield looks

  • The Wall Street Journal8 days ago

    Glaxo's Karenann Terrell Enlists AI in Understanding HIV Patients

    GlaxoSmithKline is using artificial intelligence to learn why certain HIV patients drop out of treatment. "The only clues that exist are in unstructured types of data," such as doctor's notes, ...

  • Market Realist8 days ago

    GlaxoSmithKline’s Global Pharmaceuticals Business in 3Q17

    The Global Pharmaceuticals business reported revenues of 3.1 billion pounds during 3Q17.

  • Market Realist8 days ago

    GlaxoSmithKline’s HIV Business in 3Q17

    GlaxoSmithKline’s (GSK) HIV business includes products such as Triumeq, Tivicay, Epzicom/Kivexa, and Selzentry.

  • Investors Are Undervaluing GlaxoSmithKline plc (LSE:GSK) By 32.79%, Here Is My Intrinsic Value Calculation
    Simply Wall St.8 days ago

    Investors Are Undervaluing GlaxoSmithKline plc (LSE:GSK) By 32.79%, Here Is My Intrinsic Value Calculation

    Today I will be providing a simple run-through of the discounted cash flows (DCF) method to estimate the attractiveness of GlaxoSmithKline plc (LSE:GSK) as an investment opportunity. If you wantRead More...

  • Market Realist9 days ago

    GlaxoSmithKline’s Business Segments in 3Q17

    GlaxoSmithKline’s (GSK) Vaccines segment reported revenues of ~1.7 billion pounds during 3Q17, reflecting 5.0% growth in revenues compared to 3Q16.

  • Market Realist9 days ago

    GlaxoSmithKline’s Quarterly Revenues for 3Q17

    GlaxoSmithKline's (GSK) 3Q17 revenues of ~7.8 billion pounds represented 4.0% growth compared to its 3Q16 revenues of ~7.5 billion pounds.

  • Market Realist9 days ago

    GlaxoSmithKline’s Valuation in November 2017

    In 3Q17, GlaxoSmithKline (GSK) surpassed Wall Street analysts’ estimates for its earnings per share. GSK reported revenues of ~7.8 billion pounds, missing the estimate of 7.9 billion pounds.

  • Is a Dividend Cut Coming From GlaxoSmithKline plc?
    Motley Fool11 days ago

    Is a Dividend Cut Coming From GlaxoSmithKline plc?

    Is the company's rich yield an opportunity for investors, or a warning of trouble ahead?

  • 3 Drug/Biotech Stocks in Focus on World AIDS Day
    Zacks12 days ago

    3 Drug/Biotech Stocks in Focus on World AIDS Day

    On World AIDS Day, we look into some of the key pharma companies in the HIV market that are developing drugs to address the life threatening disease.

  • Market Realist12 days ago

    Gauging Novartis’s Valuation This November

    Novartis saw revenues of ~$12.4 billion and EPS of $1.29 for 3Q17, which represents a 2% YoY rise, compared with its revenues of ~$12.1 billion in 3Q16.

  • Glaxo Begins Phase III Study on Injection to Prevent HIV
    Zacks12 days ago

    Glaxo Begins Phase III Study on Injection to Prevent HIV

    Glaxo (GSK) announces start of a large late-stage African study on an experimental long-acting injection for the prevention of HIV.

  • Glaxo Stock Down So Far This Year: Is a Reversal in Store?
    Zacks13 days ago

    Glaxo Stock Down So Far This Year: Is a Reversal in Store?

    Glaxo's shares have declined 7.9% this year so far.

  • Better Buy: GlaxoSmithKline plc vs. Pfizer
    Motley Fool13 days ago

    Better Buy: GlaxoSmithKline plc vs. Pfizer

    Want dependable and rising dividends with potential for long-term capital growth? One of these companies stands out.

  • Reuters13 days ago

    GSK starts big African study of injectable drug to prevent HIV

    ViiV Healthcare, GlaxoSmithKline Plc's HIV unit, said on Thursday it started an African study to evaluate long-acting injectable drug for the prevention of HIV infection in sexually active women. The cabotegravir study seeks to enrol 3,200 women aged 18 to 45 years from sub-Saharan African countries, ViiV Healthcare said in a statement. The HPTN 084 Phase III study will evaluate injections given every two months, ViiV Healthcare said.

  • Glaxo Submits NDA for Anti Relapse Malaria Medicine to FDA
    Zacks14 days ago

    Glaxo Submits NDA for Anti Relapse Malaria Medicine to FDA

    Glaxo (GSK) and partner Medicines for Malaria Venture filed a new drug application (NDA) with the FDA for single-dose anti relapse medicine for malaria.